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Excessive portal flow to a small remnant liver or small-for-size graft is a primary factor 
in causing small-for-size syndrome. We demonstrated that a phosphodiesterase III 
inhibitor, olprinone (OLP) showed a hepatoprotective effect by modifying portal venous 
pressure (PVP) in a rat extended hepatectomy model and small-for-size liver 
transplantation model. To identify the appropriate dose and duration of treatment for 
clinical application, we conducted the experiments, using a swine partial hepatectomy 
model. Twenty microminipigs were divided into 4 groups that received the following 
treatments: group A, control group; group B, 0.3 µg/kg/minute (min), pre- and 
postoperative administration; group C, 0.1 µg/kg/min, preoperative administration; 
group D, 0.3 µg/kg/min, preoperative administration. The pigs underwent 70% partial 
hepatectomy. Hemodynamic changes, including changes in PVP, were examined. Liver 
biopsy was performed 1 and 3 hours (h) after hepatectomy. Blood samples were 
collected until postoperative day 7. Compared with group A, PVP elevation, periportal 
edema and sinusoidal hemorrhage were attenuated after left Glisson’s ligation in groups 
C and D. Pretreatment with OLP in groups C and D preserved the microstructure of 
sinusoids and improved prothrombin activity 1 and 3 h after hepatectomy. They showed 
better recovery of remnant liver volume and plasma disappearance rate of indocyanine 
green on postoperative day 7. In contrast, group B showed exacerbation of liver damage. 
  
Measurement of serum OLP concentration showed that 10 ng/ml of OLP was 
appropriate for a hepatoprotective effect. In conclusion, Pretreatment with OLP showed 
hepatoprotective effects in a swine partial hepatectomy model. OLP may have a 
potential to ameliorate patients’ outcomes after hepatectomy or liver transplantation. 
 
  
Because of the improvement in the preoperative assessment of liver function and 
surgical techniques, liver surgery has become a safer treatment of choice and its 
indications have been expanded.1 Extended hepatectomies can be performed for the 
treatment of advanced liver cancers. Furthermore, living donor liver transplantation has 
been a treatment for end-stage liver disease because of the critical shortage of cadaveric 
organs. However, a small remnant liver or small-for-size partial graft frequently causes 
posthepatectomy liver failure (PHLF) or small-for-size syndrome (SFSS), which are 
lethal complications.2 
 To prevent PHLF or SFSS, portal venous pressure (PVP) modification is one of 
the key strategies,3 including portocaval shunt or splenic artery ligation.4,5 Clavien et al. 
reviewed strategies for safer liver resections and transplantations, focusing on 
preoperative evaluation, manipulation of liver volume, and hepatoprotective strategies 
(surgical approach and pharmacological approach).6 Among pharmacological 
approaches, several drugs have been reported to show hepatoprotective effects in rodent 
models.7-9 In particular, some drugs associated with reduction of PVP provided 
significant hepatoprotective effects.10-12 However, few drugs have been tested in large 
animal models.6 Pigs are non-primate mammals that closely resemble humans in terms 
of anatomy, physiology, and genetics,13,14 and are an ideal animal model for a 
  
preclinical study. 
 Olprinone (OLP) is a selective phosphodiesterase (PDE) III inhibitor. Elevation 
of intracellular cyclic adenosine monophosphate mediates positive inotropic effects and 
vasodilating properties.15 OLP has been used for the treatment of acute heart failure in 
cardiac surgery.16 PDE III is abundant in the liver,15 and we have demonstrated the 
hepatoprotective effects of OLP in 3 rat models: 90% partial hepatectomy model; 30% 
partial liver transplantation model; and sinusoidal obstruction syndrome model.17-19 In 
the 90% partial hepatectomy model, OLP was found to upregulate endothelial nitric 
oxide synthase (eNOS), attenuate the elevation of PVP after Glisson’s ligation, and 
preserve the microstructure of the hepatic sinusoid, resulting in improved survival rate 
after hepatectomy.18 In the rat model, OLP was administered intraperitoneally at 0.6 
µg/kg/min for 48 h before hepatectomy. However, we have no knowledge of the 
appropriate dose and duration of OLP treatment for humans.  
 In the present study, we pursued hepatoprotective properties of OLP and tried 
to demonstrate its possible beneficial effect in a swine 70 % partial hepatectomy model 
with the aim of future clinical application. 
 
MATERIALS AND METHODS 
  
 
Animals and experimental design 
Twenty female specific pathogen-free microminipigs (age, 1.5–2 years; weight, 20–23 
kg) were obtained from Fuji Micra (Shizuoka, Japan). They were randomly assigned to 
4 groups according to the dose and duration of OLP treatment (purchased from Eizai 
Pharmaceutical Co., Ltd, Japan) (Figure 1). Pigs in group A were administered saline 
(control group). Pigs in group B were administered OLP at 0.3 µg/kg/min from 3 h 
before hepatectomy to 24 h after hepatectomy (pre- and postoperative administration 
group). Pigs in groups C and D were administered OLP for 3 h until hepatectomy 
started (preoperative administration groups). Group C received a low dose of OLP (0.1 
µg/kg/min) and group D received a high dose (0.3 µg/kg/min). OLP was administered at 
2 ml/h from a central venous catheter cannulated in the right external jugular vein using 
a Baxter infusion pump (Model J2C1075J; Baxter, Deerfield, IL, USA). All animal 
experiments were conducted by the animal research committee of Kyoto University, and 
all animals were cared for in accordance with Guide for the Care and Use of Laboratory 




After an overnight fast, pigs were sedated with xylazine HCl (0.3 mg/kg), midazolam 
(0.2 mg/kg), and atropine sulfate (0.025 mg/kg) intramuscularly, and intratracheal 
intubation was performed. The pigs underwent general anesthesia with a mixture of 
oxygen/air (FiO2 0.4) and sevoflurane (1–1.5%). A heating mat was used for prevention 
of hypothermia. The infusion was performed at 20 ml/kg/h for all groups, from the 
induction of anesthesia until 3 h after hepatectomy. Muscle relaxation was sustained 
using vecuronium bromide. For control of surgical site infection, 0.5 g of cefazolin was 
prophylactically administered every 3 h from just before laparotomy. 
 
Operative procedures 
Midline laparotomy was performed. After dissecting the suspensory ligaments around 
the left lateral lobe, the hepatoduodenal ligament was skeletonized for detecting the left 
hepatic artery and portal vein. After 3 h of OLP administration, the left hepatic artery 
and the left portal vein were ligated, and hepatectomy was performed. The left lateral 
and the medial lobe were resected (defined as 70% hepatectomy).20,21 Parenchymal 
transection was performed using a monopolar electrical scalpel after addition of 
transfixation ligatures with a 1-0 braid absorbable suture on the line just proximal to a 
scheduled resection line. Small vessels in the hepatic parenchyma were ligated with 4-0 
  
braid absorbable sutures and cut. We unified a resection line of the medial lobe as a line 
that was 5 cm distant from the suprahepatic inferior vena cava. Every manipulation was 
carried out under aseptic conditions. 
 
Postoperative management 
Pigs received a 500 ml infusion of lactate Ringer’s solution on postoperative days 
(PODs) 1 and 2. They were also administered 10 mg of famotidine intravenously for 
prophylaxis of peptic ulcer, 0.5 g of cefazolin for control of surgical site infection, and 
0.1 mg of buprenorphine for pain control. Water intake was permitted from POD 1, and 




The right carotid artery and the right jugular vein were cannulated for monitoring 
arterial blood and central venous pressures (CVP), respectively. The central venous 
catheter was tunneled subcutaneously to exit behind the ear for postoperative access. 
The jejunal branch of the superior mesenteric vein was cannulated with a PE-50 catheter 
for monitoring PVP. The catheters were connected through blood pressure transducers 
  
(MLT1050, PowerLab System, ADInstruments, Pty, Ltd, Australia) and a quad bridge 
amplifier (ML118, PowerLab System, ADInstruments) to a 4-channel data-recording 
unit (ML500 PowerLab/800, PowerLab System, ADInstruments). All data were 
analyzed using the PowerLab software system. 
 
Serum total bilirubin level and prothrombin activity 
The International Study Group of Liver Surgery (ISGLS) defined posthepatectomy liver 
failure using the values of serum total bilirubin level (T-bil) and prothrombin activity 
(PT).22 For measuring T-bil and PT, blood samples were collected from the central 
venous catheter at the following time points: preoperatively; 1, 3, 6, and 24 h after 
hepatectomy; and POD 2, 3, 5, and 7. Serum and plasma were collected after 
centrifugation of blood samples for 10 min at 3500 and 3100 rpm, respectively. These 
samples were stored at –80°C for later analysis. 
 
Liver histology and immunohistochemistry 
Liver biopsy was performed at 3 time points during surgery: just before hepatectomy 
and 1 and 3 h after hepatectomy (Figure 1). Biopsy samples were fixed with 10% 
formaldehyde, embedded in paraffin wax, and sectioned at 4 µm. The slides were 
  
stained with hematoxylin and eosin. 
 Platelet/endothelial cell adhesion molecule (CD31) is frequently used to 
evaluate the microstructure of hepatic sinusoids.23 For immunostaining for CD31, tissue 
samples were directly embedded in OCT compound (Sakura Finetek, Tokyo, Japan) and 
sectioned at 4 µm. The sections were fixed with 4% paraformaldehyde for 10 min at 
4°C. To block endogenous peroxidase activity, the sections were treated with 0.3% 
H2O2 in methanol for 10 min. After blocking with DakoCytomation Protein Block 
Serum-free X0909 (Dako, Tokyo, Japan) for 30 min, the sections were incubated with a 
primary antibody recognizing porcine CD31 (MCA1746G; Serotec, Oxford, UK) at 
1:100 dilution overnight at 4°C. The sections were incubated with a labeled polymer in 
an EnVision + System HRP kit (Dako) at room temperature for 1 h. After incubation, 
the sections were examined using a Liquid DAB Substrate Chromogen System (Dako) 
and counterstained with hematoxylin. A decrease in the staining suggests a loss of the 
sinusoidal cells. The area of immunohistochemical staining was quantified 
morphometrically with ImageJ (National Institutes of Health). The total area of the 
endothelial cells was calculated from 10 randomly selected images per high-power field 
(magnification, ×200); the images were captured using a KEYENCE BZ-9000 (Japan).  
 For immunostaining for eNOS, paraffin sections were subjected to antigen 
  
retrieval in citrate buffer (10 mmol/l, pH 6.0) in a pressure cooker. After blocking, the 
sections were incubated with a primary antibody recognizing eNOS (PAB12680; 
Abnova, Taipei, Taiwan) at 1:50 dilution overnight at 4°C. Subsequently, the sections 
were incubated with a labeled polymer in an EnVision + System HRP kit (Dako) at 
room temperature for 1 h. After incubation, the sections were examined using a Liquid 
DAB Substrate Chromogen System (Dako) and counterstained with hematoxylin. 
 
Electron microscopy 
We evaluated the microstructure of hepatic sinusoids using transmission electron 
microscopy. The biopsy samples were cut into small pieces (approximately 1 mm3) and 
fixed with 2% glutaraldehyde overnight at 4°C. Thin sections were stained with 
saturated uranyl acetate and lead citrate and observed using a Hitachi H-7650 electron 
microscope. 
 
Western Blot Analysis 
We performed western blot analysis in order to compare eNOS expression levels 
between groups. Liver tissue samples were homogenized in a lysis buffer containing 10 
mmol/l Tris–HCl (pH 7.4), 150 mmol/l NaCl, 1% Nonidet P-40, and protease inhibitor. 
  
For immunoblotting, the protein (20 µg) was subjected to 10% sodium dodecyl sulfate–
polyacrylamide gel electrophoresis. After electrophoresis, the protein was transferred 
onto Immobilon-NC transfer membranes (Millipore Corporation, Billerica, MA, USA). 
These membranes were blocked with 5% skim milk in TBS-Tween and incubated with 
a primary antibody recognizing eNOS (#9572, Cell Signaling Technology, Inc. (CST), 
Danvers, MA, USA) or actin (sc-1615, Santa Cruz Biotechnology, Inc., Santa Cruz, 
CA) at a 1:1000 dilution overnight at 4°C. Furthermore, the membranes were washed 
and reacted with horseradish peroxidase – conjugated antibodies (Santa Cruz 
Biotechnology). Chemiluminescence was detected with ECL reagent (GE Healthcare 
UK Ltd., Buckinghamshire, UK) and visualized with the Ez-Capture II camera (ATTO, 
Tokyo, Japan). The intensity of the bands was quantified with ImageJ. 
 
Postoperative outcomes at POD 7 
To assess the degree of liver hypertrophy, we calculated the liver volume increase ratio 
at POD 7 using the following formula: 
(remnant liver volume at POD 7)/(resected liver volume × 3/7). 
This formula was used because 70% partial hepatectomy was performed in this 
study.20,21 The liver volume was measured in a wet condition. 
  
 In addition, to assess the degree of functional recovery of the liver, we 
calculated the ratio of plasma disappearance rate of indocyanine green (ICGk), which 
was calculated using the following formula: 
(ICGk at POD 7)/(ICGk before surgery) 
ICGk was measured using pulse dye densitometry (DDG 3000 analyzer; Nihon Kohden 
Industry, Tokyo, Japan). Details of this measurement are described elsewhere.24 In brief, 
after the pig was anesthetized and the circulation got stable, ICG (0.4 mg/kg) was 
injected through a central venous catheter and a photodetector was attached to the tail of 
the pig. Photometrical signals from each pulse were used to calculate ICGk. 
 
Serum OLP concentration 
We evaluated serum OLP concentration 6 times: before hepatectomy (control); just before 
hepatectomy (after 3 h administration of OLP); and 1, 3, 24, and 48 h after hepatectomy. 
OLP concentration was determined by ultra-fast liquid chromatography using milrinone as 
an internal standard. In brief, OLP was extracted with ethyl acetate, and the organic layer 
was evaporated to dryness. To 1.0 ml of pig serum, 30 μl of 30 μg/ml internal standard, 1 ml 
of 0.1 mol/l phosphate buffer (pH 7.0), and 5 ml of ethyl acetate were added. The residue 
was reconstituted using 200 μl of the mobile phase. Then, 50 μl of this solution was injected 
  
into an ultra-fast liquid chromatography system equipped with a reversed-phase column 
(Shim-pack XR-ODS; inside diameter, 3.0 mm; length, 100 mm; Shimadzu, Kyoto, Japan) 
and a spectrofluorometric detector with excitation/emission wavelength set at 335/400 nm. 
The mobile phase consisting of a mixture of 10 mmol/l phosphate buffer solution at pH 7.0 
and acetonitrile (88:12 [vol/vol]) was used at a flow rate of 0.5 ml/min. The retention times 
of OLP and the internal standard were 8.0 and 5.5 min, respectively. 
 
Statistical analyses 
The Student t test was used to detect differences in the continuous variables. The OLP 
treatment groups (groups B, C, and D) were compared with the control group (group A), 
and a P value <0.05 indicated statistical significance. All tests were two-sided. All 
analyses were performed using JMP software version 8 (SAS Institute Inc., Cary, NC). 
 
RESULTS 
Characteristics of the pigs in each group 
All pigs survived until POD 7 except 2 pigs in group B, who died from major bile 
leakage at POD 3 and from gastric dilation at POD 3, respectively. Thus, 18 pigs were 
analyzed in this study. The characteristics of the pigs in each group are shown in Table 
  
1. There were no significant differences with regard to body weight, resected liver 
volume, resected liver volume per body weight ratio, or estimated remnant liver 
volume.  
 
OLP attenuated the elevation of PVP after left portal vein ligation 
The results of the hemodynamic analyses, including PVP, arterial blood pressure,  
CVP, and portal to central venous pressure (PVP-CVP) gradients are shown in Figure 2. 
PVP at 10 min after left portal vein ligation was significantly lower in the OLP 
treatment groups (groups B, C, and D) than in the control group (group A) (Figure 2A). 
OLP attenuated the elevation of PVP in the acute phase. No significant differences were 
observed in arterial blood pressure except in group D at 0 min after hepatectomy. 
Hypotension due to continuous OLP administration was not observed (Figure 2B). No 
significant differences were observed in CVP in all the timings (Figure 2C). PVP-CVP 
gradient at 10 min after left portal vein ligation was significantly lower in the OLP 
treatment groups than in the control group (Figure 2D). In groups C and D, it was also 
lower than in group A at 0 min after hepatectomy. 
 
OLP pretreatment attenuated the elevation of serum total bilirubin level and 
  
prothrombin activity 
The results of T-bil and PT analyses are shown in Figure 2E and 2F. Serum T-bil level 
tended to be lower in groups C and D than in group A. In contrast, serum T-bil level 
was higher in group B, especially at 6 h after hepatectomy (statistically significant). PT 
was lower in groups C and D than in group A, especially at 1 and 3 h after hepatectomy, 
and at POD 5 (statistically significant). However, at the acute phase, PT tended to be 
higher in group B than in group A. These results indicated that OLP treatment before 
hepatectomy showed beneficial effects, but OLP treatment after hepatectomy 
aggravated posthepatectomy liver injury. 
 
 OLP pretreatment inhibited periportal edema and sinusoidal hemorrhage 
Representative photographs of hematoxylin and eosin staining are shown in Figure 3. In 
group A, periportal edema was observed 1 h after hepatectomy (Figure 3A). Within the 
swollen hepatocytes, sinusoidal hemorrhage was observed 3 h after hepatectomy 
(Figure 3B). These findings were similar to part of the pathological presentations in 
patients with SFSS.25,26 In group B, the area of the sinusoidal hemorrhage spread around 
the portal vein (Figure 3C, 3D). In contrast, in groups C and D, periportal edema was 
rarely seen, and the structure around the portal vein was normal at both 1 and 3 h after 
  
hepatectomy (Figure 3E-H). These findings suggest that OLP treatment before 
hepatectomy alleviated the hepatocyte damage caused by the elevation of PVP, but OLP 
treatment after hepatectomy resulted in exacerbation of liver damage.  
 
OLP pretreatment preserved endothelial cells in hepatic sinusoids 
The results of CD31 immunostaining are shown in Figure 4. The area of CD31 
expression before hepatectomy was 0.193. One hour after hepatectomy, it was 0.092, 
0.095, 0.13, and 0.14 in groups A, B, C, and D, respectively. Three hours after 
hepatectomy, it was 0.071, 0.067, 0.10, and 0.12, respectively. At both 1 and 3 h, 
sinusoidal endothelial cells were better preserved in groups C and D than in group A, 
with statistical significance. However, there was no significant difference between 
groups C and D. In contrast, no difference was observed between groups A and B. 
 Furthermore, we morphologically examined endothelial cell injury using 
transmission electron microscopy (Figure 5). In groups C and D, sinusoidal endothelial 
cells were well preserved (Figure 5F-I). A thin layer of fenestrated endothelium was 
covered with the space of Disse, which was filled with microvilli. In contrast, in group 
A, the sinusoidal wall was disrupted and microvilli extending from parenchymal cell 
surface were damaged (Figure 5B, 5C). In group B, the endothelial cells detached, and 
  
microvilli were lost from cell surface at 3 h after hepatectomy (Figure 5D, 5E). 
 
OLP pretreatment improved the outcomes at POD 7 
The liver volume increase ratios are shown in Figure 6. The mean values in groups A, B, 
C, and D were 2.95, 2.35, 3.63, and 3.47, respectively. Group C showed a significantly 
better outcome than did group A (P = 0.04). 
 The ICGk ratios are also shown in Figure 6. The mean values in groups A, B, C, 
and D were 1.01, 1.05, 1.28, and 1.21, respectively. Groups C and D tended to show 
better ICGk recovery than did group A. 
 On the contrary, the mean values of Ki-67 labeling indices in groups A, B, C, 
and D were 33.1, 33.0, 12.6 and 16.7%, respectively (Supplementary Figure 1). Ki-67 
was still more highly activated in groups A and B than in the OLP pretreatment groups 
(groups C and D). In a rat partial hepatectomy model, Ki-67 expression reached a peak 
at 36 h after surgery, and decreased gradually thereafter.27 In a swine 70% partial 
hepatectomy model, other indices of proliferative markers, such as thymidine kinase 
activity or mitotic index, reached a peak at POD3.28 Based on these data, we considered 
that the high activity of Ki-67 at POD7 in groups A and B indicated delayed recovery 
compared to groups C and D. 
  
 
OLP pretreatment upregulated eNOS 
We have demonstrated that hepatoprotective effects were brought about through eNOS 
upregulation in a rat model.18 We also examined whether eNOS was upregulated in the 
pig model by OLP pretreatment using liver biopsy specimens just before hepatectomy. 
Western blot analysis revealed that the levels of eNOS expression tended to be higher in 
the OLP treatment groups (groups B, C, and D) than in the control group (group A) 
(Figure 7A). The groups receiving a high dose of OLP (groups B and D) showed higher 
levels of eNOS expression than the group receiving a low dose (group C).  
 Representative photographs of immunostaining for eNOS are shown in Figure 
7B-E. Both hepatocytes and endothelial cells showed higher eNOS expression in OLP 
treatment groups than in group A. This result suggested that we were able to reproduce 
the hepatoprotective effects observed in the rat liver in our pig model. 
 
Measurement of serum OLP concentration for assessing the appropriate dose and 
treatment duration 
Serum OLP concentrations are shown in Figure 8. For observing the pharmacological 
effects of OLP, the most important time point was just before hepatectomy, when the 
  
liver was about to be exposed to surgical stress. The mean values of the OLP 
concentration just before hepatectomy were 9.7 and 32.8 ng/ml in groups C and D, 
respectively. These results suggest that a serum OLP concentration of approximately 10 
ng/ml was sufficient to obtain hepatoprotective effects. 
 In contrast, in group B, the OLP concentration increased gradually to 47.1 
ng/ml at 24 h after hepatectomy, until OLP administration was stopped. We observed 
increasing necrosis of periportal hepatocytes at 1 and 3 h after hepatectomy (Figure 3), 
when serum OLP concentrations were 26.8 and 43.4 ng/ml, respectively. This result 
indicated that if a serum OLP concentration >20 ng/ml was maintained after 
hepatectomy, posthepatectomy liver injury would be exacerbated. 
 
DISCUSSION 
We conducted the present experiments in a swine partial hepatectomy model to evaluate 
the hepatoprotective effects of OLP, a PDE inhibitor. PDE inhibitors have been reported 
to show beneficial effects on ischemia reperfusion injury of various organs, including 
the heart,29,30 liver,31,32 kidney,33 and brain.34 Inhibition of PDE leads to increased levels 
of intracellular cyclic adenosine monophosphate, followed by activation of PI3K-Akt or 
PKA-p38MAPK cascades, resulting in activation of eNOS; these mechanisms are 
  
thought to be important for the beneficial properties of these drugs. In particular, we 
focused on PVP and eNOS upregulation found in a previous rat partial hepatectomy 
model,18 and examined this efficacy in a pig model to enable translation from rats to 
humans. 
 In case of extended hepatectomy or small-for-size liver transplantation, portal 
hyperperfusion has been considered a primary factor causing PHLF or SFSS.2,6 A small 
remnant liver or graft is exposed to increased portal flow, and the endothelia of the 
sinusoids are damaged, resulting in disrupted hepatic microcirculation and necrosis of 
hepatocytes.3,23,35,36 Man et al. reported that the transient portal hypertension resulted in 
progressive and irreversible liver damage in a rat SFSS model.35 In the present study, 
OLP pretreatment attenuated the elevation of PVP in the acute phase and preserved 
hepatic microstructure, leading to better recovery at POD 7 in a swine partial 
hepatectomy model. 
 For the clinical application of OLP, the appropriate dose and treatment duration 
of OLP must be established. With regard to the pharmacokinetics of OLP in humans, 
the half-life (t½) is 1 h and continuous administration for 3 × t½ (3 h) is estimated to 
result in 88% of the plateau level of serum concentration.37 Without hepatic metabolism, 
OLP is excreted in an unchanged form in urine. For treatment of heart failure, OLP has 
  
been administered at 0.1–0.3 µg/kg/min, and the therapeutic serum concentration is 20 
ng/ml. The main effects of OLP are dose-dependent, that is, a vasodilating property at a 
low dose and a positive inotropic property at a high dose.38 For liver surgery, OLP 
concentration has to be kept sufficiently high when the liver is exposed to shear stress or 
ischemic reperfusion. We demonstrated that a serum OLP concentration of 
approximately 10 ng/ml is appropriate for obtaining a hepatoprotective effect in the pig 
model. 
 In contrast, OLP treatment after hepatectomy, which resulted in a serum OLP 
concentration >20 ng/ml, resulted in detrimental effects. These effects were not 
observed in a pig without hepatectomy, receiving continuous OLP for 48 hours with the 
serum concentration >20 ng/ml. (data not shown) One possible reason is that OLP 
increased hepatic tissue blood flow, resulting in augmented shear stress to the small 
remnant liver.35 Iribe et al. reported that OLP administration at 0.3 µg/kg/min for 2 h 
resulted in an increase in cardiac output as well as hepatic blood flow in humans.39 The 
result of the serum OLP concentration indicated that excessive OLP caused the harmful 
effect because of the increase in hepatic tissue blood flow after hepatectomy. This 
hypothesis might be supported by our experience that rats receiving OLP after  
hepatectomy showed poor prognosis. With regard to the other doses, pigs receiving 
  
pre- and postoperative OLP at 0.1 or 0.05 µg/kg/min were examined. However, they did 
not show better recovery at POD7 (data not shown). We considered that this was partly 
because serum OLP concentration after hepatectomy might have become higher than 
expected in the dehydrated pigs. All the results considered, when OLP is used in 
hepatectomy or donor hepatectomy, it should be administered only until the 
hepatectomy is finished or a partial graft is obtained. 
 Large animal research is expected to play an important role in bridging the 
knowledge gap between rats and humans. In general, there is a substantial difference 
between animal species in pharmacokinetics, mainly due to cytochrome P450 (CYP450) 
activity. However, a similarity in the primary structure of a CYP3 enzyme, which is 
responsible for the metabolism of the majority of drugs in CYP450 family, has been 
observed in pigs and humans.40 Therefore, pigs are expected to become an appropriate 
animal model for translational research, particularly for new drug discovery.14 Now we 
are conducting a phase I clinical trial (UMIN00004975), and trying to examine the 
safety and efficacy of OLP in humans based on the findings in this pig model. 
 In summary, we conducted translational research, using a swine partial 
hepatectomy model, to elucidate the appropriate dose and treatment duration of OLP in 
  




We thank Dr Rei Takahashi, Department of Pharmacotherapeutics, Faculty of 
Pharmaceutical Sciences, Doshisha Women's College of Liberal Arts, for advice on 
pathological assessment. We also thank Ms. Keiko Okamoto-Furuta and Mr. Haruyasu 
Kohda, Division of Electron Microscopic Study, Center for Anatomical Studies, 





1. Cescon M, Vetrone G, Grazi GL, Ramacciato G, Ercolani G, Ravaioli M, et al. 
Trends in Perioperative Outcome After Hepatic Resection Analysis of 1500 
Consecutive Unselected Cases Over 20 Years. Annals of Surgery. 
2009;249(6):995-1002. 
2. Dahm F, Georgiev P, Clavien PA. Small-for-size syndrome after partial liver 
transplantation: Definition, mechanisms of disease and clinical implications. American 
Journal of Transplantation. 2005;5(11):2605-10. 
3. Ogura Y, Hori T, El Moghazy WM, Yoshizawa A, Oike F, Mori A, et al. Portal 
Pressure < 15 mm Hg Is a Key for Successful Adult Living Donor Liver 
Transplantation Utilizing Smaller Grafts than Before. Liver Transplantation. 
2010;16(6):718-28. 
4. Boillot O, Delafosse B, Mechet I, Boucaud C, Pouyet M. Small-for-size partial 
liver graft in an adult recipient; a new transplant technique. Lancet. 
2002;359(9304):406-7. 
5. Troisi R, Cammu G, Militerno G, De Baerdemaeker L, Decruyenaere J, Hoste 
E, et al. Modulation of portal graft inflow: A necessity in adult living-donor liver 
transplantation? Annals of Surgery. 2003;237(3):429-36. 
  
6. Clavien P, Petrowsky H, DeOliveira ML, Graf R. Medical progress: Strategies 
for safer liver surgery and partial liver transplantation. New England Journal of 
Medicine. 2007;356(15):1545-59. 
7. Cai SR, Motoyama K, Shen KJ, Kennedy SC, Flye MW, Ponder KP. 
Lovastatin decreases mortality and improves liver functions in fulminant hepatic failure 
from 90% partial hepatectomy in rats. Journal of Hepatology. 2000;32(1):67-77. 
8. Bustos M, Beraza N, Lasarte JJ, Baixeras E, Alzuguren P, Bordet T, et al. 
Protection against liver damage by cardiotrophin-1: A hepatocyte survival factor 
up-regulated in the regenerating liver in rats. Gastroenterology. 2003;125(1):192-201. 
9. Palmes D, Skawran S, Stratmann U, Armann B, Minin E, Herbst H, et al. 
Amelioration of microcirculatory damage by an endothelin A receptor antagonist in a 
rat model of reversible acute liver failure. Journal of Hepatology. 2005;42(3):350-7. 
10. Zhao Y, Man K, Lo CM, Ng KT, Li XL, Sun CK, et al. Attenuation of 
small-for-size liver graft injury by FTY720: Significance of cell survival Akt signaling 
pathway. American Journal of Transplantation. 2004;4(9):1399-407. 
11. Man K, Lee TK, Liang TB, Lo CM, Fung PCW, Tsui SH, et al. FK 409 
ameliorates small-for-size liver graft injury by attenuation of portal hypertension and 
down-regulation of Egr-1 pathway. Annals of Surgery. 2004;240(1):159-68. 
  
12. Xu X, Man K, Zheng SS, Liang TB, Lee TK, Ng KT, et al. Attenuation of 
acute phase shear stress by somatostatin improves small-for-size liver graft survival. 
Liver Transplantation. 2006;12(4):621-7. 
13. Bendixen E, Danielsen M, Larsen K, Bendixen C. Advances in porcine 
genomics and proteomics-a toolbox for developing the pig as a model organism for 
molecular biomedical research. Briefings in Functional Genomics. 2010;9(3):208-19. 
14. Zuber R, Anzenbacherova E, Anzenbacher P. Cytochromes P450 and 
experimental models of drug metabolism. Journal of Cellular and Molecular Medicine. 
2002;6(2):189-98. 
15. Bender AT, Beavo JA. Cyclic nucleotide phosphodiesterases: Molecular 
regulation to clinical use. Pharmacological Reviews. 2006;58(3):488-520. 
16. Mizushige K, Ueda T, Yukiiri K, Suzuki H. Olprinone: A phosphodiesterase III 
inhibitor with positive inotropic and vasodilator effects. Cardiovascular Drug Reviews. 
2002;20(3):163-74. 
17. Narita M, Hatano E, Ikai I, Miyagawa-Hayashino A, Yanagida A, Nagata H, et 
al. A Phosphodiesterase III Inhibitor Protects Rat Liver From Sinusoidal Obstruction 
Syndrome Through Heme Oxygenase-1 Induction. Annals of Surgery. 
2009;249(5):806-13. 
  
18. Yamanaka K, Hatano E, Narita M, Kitamura K, Yanagida A, Asechi H, et al. 
Olprinone Attenuates Excessive Shear Stress Through Up-Regulation of Endothelial 
Nitric Oxide Synthase in a Rat Excessive Hepatectomy Model. Liver Transplantation. 
2011;17(1):60-9. 
19. Yamanaka K, Hatano E, Iguchi K, Yamamoto G, Sato M, Toriguchi K, et al. 
Effect of olprinone on liver microstructure in rat partial liver transplantation. Journal of 
surgical research. 2013;183(1):391-6. 
20. Court FG, Wemyss-Holden SA, Morrison CP, Teague BD, Laws PF, Kew J, et 
al. Segmental nature of the porcine liver and its potential as a model for experimental 
partial hepatectomy. British Journal of Surgery. 2003;90(4):440-4. 
21. Iida T, Yagi S, Taniguchi K, Hori T, Uemoto S. Improvement of 
morphological changes after 70% hepatectomy with portocaval shunt: Preclinical study 
in porcine model. Journal of Surgical Research. 2007;143(2):238-46. 
22. Rahbari NN, Garden OJ, Padbury R, Brooke-Smith M, Crawford M, Adam R, 
et al. Posthepatectomy liver failure: A definition and grading by the International Study 
Group of Liver Surgery (ISGLS). Surgery. 2011;149(5):713-24. 
23. Fondevila C, Hessheimer AJ, Taura P, Sanchez O, Calatayud D, de Riva N, et 
al. Portal Hyperperfusion: Mechanism of Injury and Stimulus for Regeneration in 
  
Porcine Small-for-Size Transplantation. Liver Transplantation. 2010;16(3):364-74. 
24. Ohwada S, Kawate S, Hamada K, Yamada T, Sunose Y, Tsutsumi H, et al. 
Perioperative real-time monitoring of indocyanine green clearance by pulse 
spectrophotometry predicts remnant liver functional reserve in resection of 
hepatocellular carcinoma. British Journal of Surgery. 2006;93(3):339-46. 
25. Kelly DM, Demetris AJ, Fung JJ, Marcos A, Zhu Y, Subbotin V, et al. Porcine 
partial liver transplantation: A novel model of the "small-for-size" liver graft. Liver 
Transplantation. 2004;10(2):253-63. 
26. Demetris AJ, Kelly DM, Eghtesad B, Fontes P, Marsh JW, Tom K, et al. 
Pathophysiologic observations and histopathologic recognition of the portal 
hyperperfusion or small-for-size syndrome. American Journal of Surgical Pathology. 
2006;30(8):986-93. 
27. Gerlach C, Sakkab DY, Scholzen T, Dassler R, Alison MR, Gerdes J. Ki-67 
expression during rat liver regeneration after partial hepatectomy. Hepatology. 
1997;26(3):573-8. 
28. Kahn D, Hickman R, Terblanche J, Vonsommoggy S. 
PARTIAL-HEPATECTOMY AND LIVER-REGENERATION IN PIGS - THE 
RESPONSE TO DIFFERENT RESECTION SIZES. Journal of Surgical Research. 
  
1988;45(2):176-80. 
29. Sanada S, Kitakaze M, Papst PJ, Asanuma H, Node K, Takashima S, et al. 
Cardioprotective effect afforded by transient exposure to phosphodiesterase III 
inhibitors - The role of protein kinase A and p38 mitogen-activated protein kinase. 
Circulation. 2001;104(6):705-10. 
30. Nomura Y, Horimoto H, Mieno S, Nakahara K, Okawa H, Yoshida M, et al. 
Repetitive preischemic infusion of phosphodiesterase III inhibitor olprinone elicits 
cardioprotective effects in the failing heart after myocardial infarction. Molecular and 
Cellular Biochemistry. 2003;248(1-2):179-84. 
31. Kobayashi T, Sugawara Y, Ohkubo T, Imamura H, Makuuchi M. Effects of 
amrinone on hepatic ischemia-reperfusion injury in rats. Journal of Hepatology. 
2002;37(1):31-8. 
32. Kume M, Banafsche R, Yamamoto Y, Yamaoka Y, Nobiling R, Gebhard M-M, 
et al. Dynamic changes of post-ischemic hepatic microcirculation improved by a 
pre-treatment of phosphodiesterase-3 inhibitor, milrinone. Journal of Surgical Research. 
2006;136(2):209-18. 
33. Mizutani A, Murakarni K, Okajima K, Kira S, Mizutani S, Kudo K, et al. 
Olprinone reduces ischemia/reperfusion-induced acute renal injury in rats through 
  
enhancement of cAMP. Shock. 2005;24(3):281-7. 
34. Genovese T, Mazzon E, Paterniti I, Esposito E, Cuzzocrea S. Neuroprotective 
effects of olprinone after cerebral ischemia/reperfusion injury in rats. Neuroscience 
Letters. 2011;503(2):93-9. 
35. Man K, Lo CM, Ng IOL, Wong YC, Qin LF, Fan ST, et al. Liver 
transplantation in rats using small-for-size grafts - A study of hemodynamic and 
morphological changes. Archives of Surgery. 2001;136(3):280-5. 
36. Man K, Fan ST, Lo CM, Liu CL, Fung PCW, Liang TB, et al. Graft injury in 
relation to graft size in right lobe live donor liver transplantation - A study of hepatic 
sinusoidal injury in correlation with portal hemodynamics and intragraft gene 
expression. Annals of Surgery. 2003;237(2):256-64. 
37. Kakihana Y. Phosphodiesterase III inhibitor. Anesthesia 21 Century. 
2008;10(2-31):32-40. 
38. Adachi H, Kamata S, Kodama K, Nagakura T. Vasorelaxant effect of a 
phosphodiesterase 3 inhibitor, olprinone, on isolated human radial artery. European 
Journal of Pharmacology. 2000;396(1):43-7. 
39. Iribe G, Yamada H, Matsunaga A, Yoshimura N. Effects of the 
phosphodiesterase III inhibitors olprinone, milrinone, and amrinone on 
  
hepatosplanchnic oxygen metabolism. Critical Care Medicine. 2000;28(3):743-8. 
40. Monshouwer M, van't Klooster GAE, Nijmeijer SM, Witkamp RF, van Miert A. 
Characterization of cytochrome P450 isoenzymes in primary cultures of pig hepatocytes. 





Figure 1. Details of the 4 groups according to the dose of OLP, treatment time, and 
timings of liver biopsy 
 
Figure 2. Results of the hemodynamic (A–D) and biochemical studies (E, F): (A) portal 
venous pressure; (B) systolic arterial blood pressure; (C) central venous pressure; (D) 
PVP to CVP gradient; (E) serum total bilirubin level; and (F) prothrombin time. *P < 
0.05, vs. group A. 
 
Figure 3. Representative photographs of hematoxylin and eosin staining (×100). In 
group A, swollen hepatocytes were observed 1 h after hepatectomy in the periportal 
area (A), and sinusoidal hemorrhage spread within periportal connective tissues 3 h 
after hepatectomy (B). In group B, these findings were more marked. Necrosis of 
hepatocytes was observed 1 h after hepatectomy (C and C’ (×200)), and sinusoidal 
hemorrhage was more severe (D and D’ (×200)). In contrast, in groups C and D, these 
findings were rarely observed, and the structure around the portal vein was preserved 
both 1 h (E, G) and 3 h (F, H) after hepatectomy. 
 
  
Figure 4. Representative photographs of immunostaining for CD31 (×100). (A) Control 
pigs before surgery; (B, C) group A 1 and 3 h after hepatectomy; (D, E) group B 1 and 3 
h after hepatectomy; (F, G) group C 1 and 3 h after hepatectomy; (H, I) group D 1 and 3 
h after hepatectomy. (J) The relative CD31 expression was quantified morphometrically. 
The data are expressed as the mean and standard deviation. *P < 0.05 vs. group A). 
 
Figure 5. Micrographs of hepatic sinusoids on transmission electron microscopy 
(×4000). (A) Control pigs before surgery; (B, C) group A 1 and 3 h after hepatectomy; 
(D, E) group B 1 and 3 h after hepatectomy; (F, G) group C 1 and 3 h after 
hepatectomy; (H, I) group D 1 and 3 h after hepatectomy. Asterisks indicate the space 
of Disse, and arrows indicate endothelial cells. 
 
Figure 6. The results of the (A) liver volume increase ratio at POD 7, and (B) ICGk 
ratio at POD 7. The liver volume increase ratio at POD 7 was calculated using the 
following formula: (remnant liver volume at POD 7)/(resected liver volume × 3/7). This 
formula was based on an approximate value considering that the procedure used in this 
study was 70% partial hepatectomy.20,21 The ICGk ratio was calculated using the 
following formula: (ICGk at POD 7)/(ICGk before surgery). The data are expressed as 
  
the mean and standard deviation. *P < 0.05 vs. group A.  
 
Figure 7. (A) Western blot analysis of hepatic eNOS just before hepatectomy. The 
relative eNOS levels were quantified by densitometry. The data are expressed as the 
mean and standard deviation. (B-E) Representative photographs of immunostaining for 
eNOS just before hepatectomy (×200). (B) Group A; (C) group B; (D) group C; (E) 
group D. Staining of eNOS in hepatocytes and endothelial cells was more prominent in 
OLP treatment groups than in group A. Arrows indicate endothelial cells.  
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TABLE 1 Characteristics of the pigs in each group 
Characteristic A (n = 5) B (n = 3) C (n = 5) D (n = 5) 
Body weight (kg)  21.4 21.5 20.9 22.2 
Resected liver volume (kg)  0.21 0.23 0.21 0.21 
Resected liver volume/body weight  0.010 0.011 0.010 0.010 
Estimated remnant liver volume (kg)a  0.09 0.11 0.09 0.09 
Values are means. 
aEstimated remnant liver volume was calculated by multiplying 3/7 by the resected liver 
volume, which was based on an approximate value considering that the procedure used 
in this study was 70% partial hepatectomy.20,21 
 
S u p p l e m e n t a r y  F i g u r e  1
